Grifols achieves EMA certification for its value chain in Egypt and opens the way to exports to Europe

 

Grifols Egypt obtains European approval: a milestone for healthcare and foreign trade

Griffols It has marked a turning point in the international pharmaceutical industry. The multinational has received certification from European Medicines Agency (EMA) for the entire value chain of Grifols Egypt for Plasma Derivates (GEPD)This recognition validates that the Egyptian platform operates under the most demanding standards of quality, safety and regulatory control. European Union.

 

This accreditation has immediate geopolitical and logistical significance: it makes Egypt the first country to Africa and Middle East Egypt has a fully integrated, internationally certified plasma collection and processing system. From donor evaluation to final delivery, the entire cycle complies with European regulations, enabling Egypt to export its surplus blood products to other markets, with a particular focus on Europe.

 

Tomás Dagá, VP Grifols EgyptDagá highlighted the magnitude of the achievement: “This certification confirms the quality and rigor of the work carried out by the teams involved over the past five years to create Africa’s first integrated plasma platform.” He emphasized that the European certification “guarantees that medicines derived from this plasma can be distributed to markets that need them, once Egypt’s domestic needs are met.”

 

Self-sufficiency and a new regional logistics hub

 

The joint strategy between the Egyptian government and the pharmaceutical company has allowed the North African country to reach 100% self-sufficiency in blood products. With this advance, Egypt enters the select club of nations capable of being self-sufficient in medicines derived from national plasma, a milestone that until now only five Western countries held.

 

World Ranking of Plasma Self-Sufficiency
1 U.S
2. Germany
3. austria
4 Czech Republic
5 Hungary
6. Egypt (New Entry)

 

This status not only covers domestic demand, but also positions Egypt as a regional hub key to supplying Africa and the Middle East, strengthening the continent's health resilience.

 

Reducing strategic dependence on Europe

 

The certification comes at a critical time for global healthcare logistics. Currently, the 65% of the world's plasma It comes from the United States. Europe, for its part, imports about 40 % of their needs from that country, an external dependence that the EMA and the new SoHo regulation seek to mitigate.

 

Project validation Grifols Egypt It offers a robust alternative. By diversifying supply sources with a close and certified partner like Egypt, Europe strengthens its security of supply against potential disruptions in the transatlantic logistics chain. Blood products are considered critical medicines for treating chronic and rare diseases for which there are no viable alternative treatments.

 

Economic impact and industrial infrastructure

The project is based on a public-private partnership that has mobilized a joint investment of 280 millones de eurosThe current facilities include 16 donation centers (with plans for 20 by 2026), a state-of-the-art laboratory, and a comprehensive logistics center. Furthermore, the processing plant is expected to become operational in 2026, completing the industrialization of the process in Egypt.

 

The following are the key figures regarding the economic and social impact of the project:

Indicator	Data / Projection
Joint initial investment	280 millones de euros
Contribution to Egyptian GDP (2025)	55 millones de euros
Annual contribution to GDP (est. 2030)	> 272 million euros
Cumulative clinical impact	> 80 million euros in health benefits
Current direct employment	1.200 skilled positions
Employment projection (2026-2029)	186.000 new jobs (direct, indirect and induced)

 

The initiative also stands out for its knowledge transfer component. Grifols Academy for Plasmapheresis It has provided more than 170.000 hours of training, enabling local staff to operate autonomously under international standards.

 

Key points and frequently asked questions about Grifols Egypt certification

What does EMA certification mean for Grifols Egypt?
This means that the entire plasma value chain in Egypt (donation, analysis, processing, and distribution) meets the European Union's rigorous safety and quality standards. This allows Egypt to export its surplus plasma-derived medicines to Europe and other regulated markets.

How does this project benefit the European Union?
This helps reduce Europe's strategic dependence on plasma from the United States (currently 40% of European imports). Egypt becomes a nearby, alternative healthcare hub, strengthening the security of supply for these critical medications.

What is the economic impact for Egypt?
The project, with an initial investment of 280 million euros, will contribute 55 million to GDP in 2025 and is expected to generate more than 186.000 total jobs between 2026 and 2029. In addition, it has made Egypt the sixth country in the world self-sufficient in blood products.